Evidence map›Paper›PMID 38341456›Full record

ReviewScientific reports2024

The effects of OPRM1 118A>G on methadone response in pain management in advanced cancer at end of life.

Larisa M Haupt, Alison Haywood, Heidi G Sutherland, Chieh Yu, Cassie L Albury, Anushka Pharasi, Mathew Zunk, Rani George, Lyn R Griffiths, Phillip Good and 1 more

Open access · goldAbstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in Scientific reports, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
0.6field-weighted citation impact, top 35% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 1 citations in OpenAlex.

  1. Cancer pain.Nature reviews. Disease primers · 2026
    Review
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors at 6 institutions in 3 countries.

Larisa M HauptCentre for Genomics and Personalised Health, Genomics Research Centre, School of Biomedical Sciences, Queensland University of Technology, Brisbane, Australia. larisa.haupt@qut.edu.au.
Alison HaywoodSchool of Pharmacy and Medical Sciences, Griffith University, Gold Coast, Australia. a.haywood@griffith.edu.au.
Heidi G SutherlandCentre for Genomics and Personalised Health, Genomics Research Centre, School of Biomedical Sciences, Queensland University of Technology, Brisbane, Australia.
Chieh YuCentre for Genomics and Personalised Health, Genomics Research Centre, School of Biomedical Sciences, Queensland University of Technology, Brisbane, Australia.
Cassie L AlburyCentre for Genomics and Personalised Health, Genomics Research Centre, School of Biomedical Sciences, Queensland University of Technology, Brisbane, Australia.
Anushka PharasiSchool of Pharmacy and Medical Sciences, Griffith University, Gold Coast, Australia.
Mathew ZunkSchool of Pharmacy and Medical Sciences, Griffith University, Gold Coast, Australia.
Rani GeorgeSchool of Pharmacy and Medical Sciences, Griffith University, Gold Coast, Australia.
Lyn R GriffithsCentre for Genomics and Personalised Health, Genomics Research Centre, School of Biomedical Sciences, Queensland University of Technology, Brisbane, Australia.
Phillip GoodMater Research Institute-The University of Queensland, Brisbane, Australia.
Janet HardyMater Research Institute-The University of Queensland, Brisbane, Australia.
Queensland University of Technology · AUGriffith University · AUMater Research · AUMax Planck Society · DEMetro South Health · AUSt Vincent’s Private Hospital Brisbane · AU

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Cancer pain is the most feared symptom at end of life. Methadone has advantages over other opioids but is associated with significant variability in clinical response, making dosing challenging in practice. OPRM1 is the most studied pharmacogene associated with the pharmacodynamics of opioids, however reports on the association of the A118G polymorphism on opioid dose requirements are conflicting, with no reports including methadone as the primary intervention. This association study on OPRM1 A118G and response to methadone for pain management, includes a review of this genetic factor's role in inter-patient variability. Fifty-four adult patients with advanced cancer were recruited in a prospective, multi-centre, open label dose individualization study. Patient characteristics were not shown to influence methadone response, and no significant associations were observed for methadone dose or pain score. The findings of our review of association studies for OPRM1 A118G in advanced cancer pain demonstrate the importance of taking ancestry into account. While our sample size was small, our results were consistent with European populations, but in contrast to studies in Chinese patients, where carriers of the A118G polymorphism were associated with higher opioid dose requirements. Pharmacogenetic studies in palliative care are challenging, continued contribution will support future genotype-based drug dosing guidelines.

Indexed as

Cancer PainNeoplasmsAdultAnalgesics, OpioidGenotypeHumansMethadonePain ManagementPolymorphism, Single NucleotideProspective StudiesReceptors, Opioid, muAnalgesics, OpioidMethadoneOPRM1 protein, humanReceptors, Opioid, mu

Identifiers

PMID38341456
PMCPMC10858860
OpenAlexW4391721997

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.